Skip to main content
Signal8

Sarepta Therapeutics, Inc. (SRPT)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Sarepta Therapeutics, Inc. logo

Sarepta Therapeutics, Inc.

NASDAQ:SRPTHealthcare
Pre+2.08%$18.19
Close$17.82+1.42%AH$17.82+2.08%since
Mkt Cap$1.91B
Float98.25M
O/S107.24M
PM VOL171 sh
$ Vol≈$3K
RVOL0.85×
Inst Own97.9%
SI22.7%
Dilution
Sarepta Therapeutics, Inc. logoNASDAQ:SRPTPre$18.19+2.08%
Historical Data
DateOpenHighLowCloseVolume
Nov 6, 202618.7718.7717.5217.822,596,796
Nov 5, 202618.9118.9217.4417.571,871,621
Nov 4, 202618.9419.2818.5218.991,482,485
Nov 3, 202618.4418.8018.2518.541,398,499
Nov 2, 202618.6518.9018.1018.321,159,345
Oct 30, 202619.0419.5018.4118.621,318,156
Oct 29, 202619.2019.6818.9619.231,188,092
Oct 28, 202618.7719.3318.5019.321,356,735
Oct 27, 202618.0518.8917.6918.892,226,641
Oct 26, 202617.7718.1417.6617.981,361,777
Oct 23, 202617.9418.1217.1617.731,285,459
Oct 22, 202618.4018.9418.1118.181,235,540
Oct 21, 202619.0519.3018.4918.562,034,185
Oct 20, 202617.7419.7017.6619.173,327,346
Oct 19, 202617.2517.8317.1217.732,329,410
Oct 16, 202617.8217.8416.8517.109,856,184
Oct 15, 202616.9617.9516.6117.794,041,905
Oct 14, 202616.5316.9116.3716.832,741,334
Oct 13, 202617.1217.2316.4116.513,689,044
Oct 12, 202617.8818.1417.3017.443,282,803
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not available
Ratings Distribution
BUY
30
HOLD
18
SELL
6
TOTAL54
Insider Trades
InsiderTypeShares
Rodino-Klapac Louise profile photoRodino-Klapac LouiseAutomatic Sell21.4K
Wong Ryan Ho-Yan profile photoWong Ryan Ho-YanAutomatic Sell13.3K
Estepan Ian Michael profile photoEstepan Ian MichaelAutomatic Sell24.8K
Rothfuss Cristin profile photoRothfuss CristinAutomatic Sell22.0K
SEVERINO MICHAEL profile photoSEVERINO MICHAELGrant/Award2.22M
SEVERINO MICHAEL profile photoSEVERINO MICHAELGrant/Award756.1K
Shareholders
97.9%
Institutional
(321)
5.4%
Insiderⓘ
(16)
5.9%
5%+ Owners
(2)
-
Unattributed (incl. retail)ⓘ
Institutional97.9%
Insider5.4%
5%+ Beneficial5.9%
Sources: 13F, Form 4, 13D/13GO/S: 107.2M · as of 2 Nov 2026 · SEC cover page
Insiders & Institutional Holders

Insiders

Top institutional holders

About

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases.

The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies.

The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.

Key Metrics
Market Cap$1.91B
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership97.87%

based on 107.24M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUSUS
IPO DateJun 4, 1997
Shares Outstanding107.24M
Authorized Shares
Float98.25M
52-Week Range
$14.68$25.32
$17.82(30th percentile)
Volume
Average Daily Volume2.49M
2.60M today vs 2.49M avg(+4%)

30d Avg

2.49M

60d Avg

2.57M

90d Avg

2.75M

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...